Open AccessTicagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey
Author(s) -
Ran Eliaz,
Bethlehem Mengesha,
Tal Ovdat,
Zaza Iakobishvili,
David Hasdai,
Mark Kheifets,
Robert Klempfner,
Roy Beigel,
Eran Kalmanovich,
Ronny Alcalai,
Amos Levi
Publication year - 2021
Publication title -
cardiology
Language(s) - English
Resource type - Journals
eISSN - 1421-9751
pISSN - 0008-6312
DOI - 10.1159/000521042
Subject(s) - prasugrel , medicine , ticagrelor , acute coronary syndrome , percutaneous coronary intervention , cardiology , myocardial infarction , mace
We aimed to compare the outcomes of acute coronary syndrome (ACS) patients undergoing in-hospital percutaneous coronary intervention treated with prasugrel versus ticagrelor. Methods: Among 7,233 patients enrolled to the Acute Coronary Syndrome Israeli Survey (ACSIS) between 2010 and 2018, we identified 1,126 eligible patients treated with prasugrel and 817 with ticagrelor. Comparison between the groups was performed separately in ST-elevation myocardial infarction (STEMI) patients, propensity score matched (PSM) STEMI patients, and non-ST-elevation ACS (NSTE-ACS) patients. Results: In-hospital complication rates, including rates of stent thrombosis, were not significantly different between groups. In PSM STEMI patients, 30-day re-hospitalization rate ( p < 0.05), 30-day MACE (the composite of death, MI, stroke, and urgent revascularization, p = 0.006), and 1-year mortality rates ( p = 0.08) were higher in the ticagrelor group compared to the prasugrel group; in NSTE-ACS patients, outcomes were not associated with drug choice. In Cox regression analysis applied on the entire cohort, prasugrel was associated with lower 1-year mortality in STEMI patients but not in NSTE-ACS patients ( p for interaction 0.03). Conclusions: Compared to ticagrelor, prasugrel was associated with superior clinical outcomes in STEMI patients, but not in NSTE-ACS patients.